Side-by-side · Research reference

CardiogenvsRetatrutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BPhase 2HUMAN-REVIEWED10/41 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

01Mechanism of Action

Parameter

Cardiogen

Retatrutide

Primary target

Cardiovascular cell gene expressionKhavinson 2022

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

Retatrutide

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

Once weekly

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Route

Subcutaneous injection

—

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

Indefinite for chronic indication (presumed)

Titration schedule

—

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

Reconstitution

—

Investigational; not commercially available

Timing

—

Any time of day

Half-life

—

~6 days (estimated from class)

04Side Effects & Safety

Parameter

Cardiogen

Retatrutide

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

Heart rate

—

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

Glucose handling

—

Glycemic improvement; rare hyperglycemia from glucagon component

Pancreatitis risk

—

Class warning

Thyroid C-cell tumours

—

Class warning (presumed)

Pregnancy / OB

—

Avoid (insufficient data)

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

05Administration Protocol

Parameter

Cardiogen

Retatrutide

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Variable — often evening injection. No established circadian preference.

Once weekly, same day.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

Refrigerate 2–8 °C. Light-protected.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

Retatrutide

— no documented stacks